Author(s)
Martinez I1, Barrios V2, Pallares V3, Campuzano R4, Castellanos M5, Gomez Cerezo J6, Egocheaga I7, Games JM8, Morant Talamante N9, Rodriguez Barrios JM9, Sicras-Mainar A10, Pérez Román I11, Parrondo García FJ12, Mostaza JM13
1Son Spases University Hospital, Palma de Mallorca, Spain, 2Ramon Cajal University Hospital, Madrid, M, Spain, 3Unión de Mutuas, Castellón, Spain, 4Alcorcón Foundation University Hospital, Alcorcón, Spain, 5A Coruña University Hospital & Biomedical Research institute, A Coruña, Spain, 6Infanta Sofia University Hospital, Madrid, Spain, 7Clinic Centre Isla de Oza, Madrid, Spain, 8Son Llazer University Hospital, Palma de Mallorca, Spain, 9Novartis Spain, Barcelona, M, Spain, 10Atrys Health, Barcelona, Spain, 11Atrys Health, Madrid, M, Spain, 12Novartis Spain, Coslada, M, Spain, 13La Paz University Hospital, Madrid, Spain
BACKGROUND: Ischemic heart disease angina and acute myocardial infarction (AMI) are one of the main causes of morbidity and mortality in developed countries and entails a high resources consumption and costs for health systems. The risk of suffering future CV events and the consequent consumption of resources is increased in those patients who have suffered a previous AMI. OBJECTIVES:
Estimate the average annual cost per patient with a new diagnosis or new episode of angina and AMI.
METHODS:
A retrospective observational study of the electronic medical records of patients from the BIG-PAC® database (patients from 7 integrated areas of 7 Spanish Regions; n=1.8 million) was carried out. Patients with a new/recurrent Ischemic heart disease episode between 1/1/2017 and 12/31/2018 were included. Direct healthcare costs (DHCC) were calculated from the consumption of resources during follow-up (two years from diagnosis) and the mean of the Regions official published tariff. The indirect non-health costs (INHCC) associated with the loss of productivity were determined. All costs were updated to €2021.
RESULTS:
A total of 12,350 patients (6,794 with angina and 5,556 with AMI) were detected in the recruitment period. During follow-up, 3,512 patients (28,5%) (2,134 with angina and 1,378 with AMI) suffered a new Cardiovascular event and 798 (6,5%) died (500 with angina and 298 with AMI). The mean costs per patient in the first year were €9,512 (angina) and €8,679 (AMI) (DHCC) and €1,966 (angina) and €1,961 (AMI) (INHCC) and €8,566 (DHCC) and €2,277 (INHCC) for angina and €7,548 (DHCC) and €2,112 (INHCC) for AMI in the second year.
CONCLUSIONS:
Patients with ischemic heart disease have a high mortality and represent a considerable social and healthcare cost. Developing preventive programs including primary care, cardiac rehabilitation and controlling cardiovascular risk factors could help reduce mortality and cost for the Spanish National Health System.
Conference/Value in Health Info
2022-11, ISPOR Europe 2022, Vienna, Austria
Value in Health, Volume 25, Issue 12S (December 2022)
Code
EE84
Topic
Economic Evaluation
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory)